GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AVANIR Pharmaceuticals (FRA:AV2B) » Definitions » Quick Ratio

AVANIR Pharmaceuticals (FRA:AV2B) Quick Ratio : 9.35 (As of Sep. 2014)


View and export this data going back to . Start your Free Trial

What is AVANIR Pharmaceuticals Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. AVANIR Pharmaceuticals's quick ratio for the quarter that ended in Sep. 2014 was 9.35.

AVANIR Pharmaceuticals has a quick ratio of 9.35. It generally indicates good short-term financial strength.

The historical rank and industry rank for AVANIR Pharmaceuticals's Quick Ratio or its related term are showing as below:

FRA:AV2B' s Quick Ratio Range Over the Past 10 Years
Min: 0.29   Med: 4.13   Max: 10.96
Current: 9.35

During the past 13 years, AVANIR Pharmaceuticals's highest Quick Ratio was 10.96. The lowest was 0.29. And the median was 4.13.

FRA:AV2B's Quick Ratio is not ranked
in the Drug Manufacturers industry.
Industry Median: 1.33 vs FRA:AV2B: 9.35

AVANIR Pharmaceuticals Quick Ratio Historical Data

The historical data trend for AVANIR Pharmaceuticals's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVANIR Pharmaceuticals Quick Ratio Chart

AVANIR Pharmaceuticals Annual Data
Trend Sep05 Sep06 Sep07 Sep08 Sep09 Sep10 Sep11 Sep12 Sep13 Sep14
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.18 5.93 3.96 2.04 9.35

AVANIR Pharmaceuticals Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.04 1.73 2.01 3.04 9.35

Competitive Comparison of AVANIR Pharmaceuticals's Quick Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, AVANIR Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AVANIR Pharmaceuticals's Quick Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AVANIR Pharmaceuticals's Quick Ratio distribution charts can be found below:

* The bar in red indicates where AVANIR Pharmaceuticals's Quick Ratio falls into.



AVANIR Pharmaceuticals Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

AVANIR Pharmaceuticals's Quick Ratio for the fiscal year that ended in Sep. 2014 is calculated as

Quick Ratio (A: Sep. 2014 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(233.434-0.62)/24.904
=9.35

AVANIR Pharmaceuticals's Quick Ratio for the quarter that ended in Sep. 2014 is calculated as

Quick Ratio (Q: Sep. 2014 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(233.434-0.62)/24.904
=9.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AVANIR Pharmaceuticals  (FRA:AV2B) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


AVANIR Pharmaceuticals Quick Ratio Related Terms

Thank you for viewing the detailed overview of AVANIR Pharmaceuticals's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AVANIR Pharmaceuticals (FRA:AV2B) Business Description

Traded in Other Exchanges
N/A
Address
Avanir Pharmaceuticals was incorporated in California in August 1988 and was reincorporated in Delaware in March 2009. The Company is a biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. The Company commenced promotion of NUEDEXTA in the United States in February 2011. The Company is also studying AVP-923 for use in different types of neuropathic pain. NUEDEXTA is the first and only FDA-approved treatment for pseudobulbar affect. NUEDEXTA is an combination of two components: dextromethorphan hydrobromide, the ingredient that is harmacologically active in the central nervous system, and quinidine sulfate, a metabolic inhibitor enabling dextromethorphan to reach therapeutic plasma concentrations. The Company currently markets NUEDEXTA to approximately 10,000 physicians and other healthcare providers who specialize in psychiatry, neurology or geriatric medicine and practice in outpatient or long-term care settings. NUEDEXTA may face competition from several products: Antidepressants, including Prozac, Celexa, Zoloft, Paxil, Elavil and Pamelor and others; Atypical antipsychotic agents, including Zyprexa, Risperdal, Seroquel, Abilify, Geodon and others; and Miscellaneous agents, including Symmetrel, Lithium and others. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substance Control Act, the Export Control Act and other present and future laws of general application.

AVANIR Pharmaceuticals (FRA:AV2B) Headlines

No Headlines